Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,705,654 papers from all fields of science
Search
Sign In
Create Free Account
AR C124910XX
Known as:
AR-C124910XX
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Adenosine
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
R. Storey
,
D. Angiolillo
,
+12 authors
M. Sabatine
Journal of the American College of Cardiology
2016
Corpus ID: 31674705
2015
2015
Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo- -controlled…
P. Adamski
,
M. Ostrowska
,
+8 authors
M. Koziński
2015
Corpus ID: 55902450
Background. Therapy with aspirin and one of the platelet P2Y12 receptor inhibitors, preferably ticagrelor or prasugrel, is the…
Expand
Highly Cited
2015
Highly Cited
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective…
F. Franchi
,
F. Rollini
,
+11 authors
D. Angiolillo
JACC. Cardiovascular interventions
2015
Corpus ID: 205796765
2015
2015
Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
H. Jeon
,
M. Kim
,
+6 authors
Hyeong-Seok Lim
Clinical therapeutics
2015
Corpus ID: 5847269
Highly Cited
2015
Highly Cited
2015
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study
D. Alexopoulos
,
N. Barampoutis
,
+8 authors
I. Xanthopoulou
Clinical Pharmacokinetics
2015
Corpus ID: 19784514
ObjectiveThe objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered…
Expand
2012
2012
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects
R. Teng
,
P. Mitchell
,
K. Butler
European Journal of Clinical Pharmacology
2012
Corpus ID: 17923015
PurposeTicagrelor, a reversibly binding oral P2Y12 receptor antagonist, is predominantly metabolized by cytochrome P450 3A and…
Expand
2012
2012
Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers
R. Teng
,
P. Mitchell
,
K. Butler
Journal of clinical pharmacy and therapeutics
2012
Corpus ID: 24146600
What is known and Objective: Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist and has been approved in…
Expand
Highly Cited
2010
Highly Cited
2010
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
R. Teng
,
S. Oliver
,
M. A. Hayes
,
K. Butler
Drug Metabolism and Disposition
2010
Corpus ID: 22084793
Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d…
Expand
Highly Cited
2010
Highly Cited
2010
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.
Henrik Sillén
,
M. Cook
,
P. Davis
Journal of chromatography. B, Analytical…
2010
Corpus ID: 20116693
Highly Cited
2009
Highly Cited
2009
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
R. Teng
,
K. Butler
European Journal of Clinical Pharmacology
2009
Corpus ID: 23490203
PurposeTicagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist in development for reduction of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE